Discover how Regeneron (NASDAQ: REGN) harmonizes biology and technology to create life-changing medicines. Join our team and explore clinical trials.

On February 4, 2020, the U.S. Department of Health and Human Services, which already worked with Regeneron, announced that Regeneron would pursue monoclonal antibodies to fight …

Regeneron is a leading biotechnology company dedicated to inventing, developing and commercializing life-transforming medicines for people with serious diseases.

Dec 20, 2025 · Regeneron is set for a turnaround as Dupixent and Libtayo drive growth, and 2026 pipeline catalysts may boost revenue. See why REGN stock is a strong buy.

Jul 2, 2025 · Regeneron Pharmaceuticals said on Wednesday the U.S. Food and Drug Administration has approved its drug for a type of blood cancer called multiple myeloma that …

Dec 22, 2025 · Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases.

5 days ago · A detailed overview of Regeneron Pharmaceuticals, Inc. (REGN) stock, including real-time price, chart, key statistics, news, and more.

Dec 10, 2025 · The Investor Relations website contains information about Regeneron Pharmaceuticals Inc.'s business for stockholders, potential investors, and financial analysts.

The Regeneron ISEF event week will be held from May 9-15, 2026 at the Phoenix Convention Center. More than 500 volunteers will be needed across a spectrum of activities!

Dec 23, 2025 · About Regeneron Pharmaceuticals Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, …